Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention

被引:15
|
作者
Youssef, Ali A.
Wu, Chiung-Jen
Hang, Chi-Ling
Cheng, Cheng-I
Yang, Cheng-Hsu
Chen, Chien-Jen
Chen, Yen-Hsun
Chai, Han-Tan
Chua, Sarah
Yeh, Kuo-Ho
Yip, Hon-Kan
机构
[1] Chang Gung Univ Coll Med, Dept Internal Med, Div Cardiol, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung 83301, Taiwan
[2] Suez Canal Univ Hosp, Dept Cardiol, Ismailia, Egypt
关键词
nitroprusside; no-reflow; PercuSurge device; slow-flow;
D O I
10.1253/circj.70.1538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study tested the hypothesis that when administered in conjunction with a PercuSurge device for treatment of acute myocardial infarction (AMI), intracoronary (IC) administration of nitroprusside (NTP) is safe and superior to IC administration of NTP alone or nitroglycerin (NTG) for reversing slow-flow or no-reflow, both of which occur frequently during primary percutaneous coronary intervention (PCI). Methods and Results Sixty-two patients with ST-segment elevation AMI of < 12h duration undergoing primary PCI were enrolled. When the final Thrombolysis In Myocardial Infarction (TIMI) flow was normal (TIMI-3), NTG 200 mu g was administered first, followed by (5 min later) NTP 100,mu g via an intra-guiding catheter. When final TIMI flow was <= 2, NTG 200 mu g was given, followed by NTP 100 mu g via an export suction catheter advanced into the infract-related artery (IRA). Primary endpoint was epicardial blood flow (TIMI-flow), corrected TIMI frame counts, or microvascular circulation [myocardial blush (MB) grade]. Analytical results indicated that the final TIMI-3 flow was significantly higher in patients receiving NTP than in those receiving NTG therapy (100% vs 88.7%, p=0.023). As compared with NTG, NTP therapy significantly improved final MB grade (p < 0.0001) and corrected TIMI flame count time (p < 0.0001). Subgroup analysis demonstrated that final MB grade (p < 0.001) and corrected TIMI flame count time (p < 0.01) were significantly higher in patients (n=33) with than in patients (n=29) without the PercuSurge. No significant NTP related adverse events occurred, apart from insignificant transient hypotension. Conclusion IC administration of NTP is safe and superior to NTG for improving final epicardial blood flow and microvascular circulation in patients with AMI undergoing primary PCI. Combination therapy of PercuSurge device and NTP provided an additional benefit to NTP alone for improving microvascular circulation.
引用
收藏
页码:1538 / 1542
页数:5
相关论文
共 50 条
  • [31] No-Reflow Phenomenon in Primary PCI of AMI: Effect of Super-Selective Intracoronary Injection of Nitroprusside
    Sun Jiaan
    CIRCULATION, 2010, 122 (02) : E250 - E250
  • [32] The no-reflow phenomenon associated with percutaneous coronary intervention: Its mechanisms and treatment
    Ito H.
    Cardiovascular Intervention and Therapeutics, 2011, 26 (1) : 2 - 11
  • [33] Atrial Fibrillation: A Novel Risk Factor for No-Reflow Following Primary Percutaneous Coronary Intervention
    Kaya, Adnan
    Keskin, Muhammed
    Tatlisu, Mustafa Adem
    Uzman, Osman
    Borklu, Edibe
    Cinier, Goksel
    Yildirim, Ersin
    Kayapinar, Osman
    ANGIOLOGY, 2020, 71 (02) : 175 - 182
  • [34] Intracoronary nitroprusside versus verapamil for the prevention of no/slow reflow phenomenon in patients undergoing primary percutanous coronary intervention
    Abdelaziz, H.
    Khaled, S.
    Khairy, T.
    Thabet, S.
    Elkelany, W.
    Rashid, T.
    EUROPEAN HEART JOURNAL, 2015, 36 : 826 - 826
  • [35] Efficacy and safety of local intracoronary drug delivery in the distal coronary bed as treatment of no-reflow phenomenon during percutaneous coronary intervention
    Graidis, C.
    Graidis, S.
    Dimitriadis, D.
    Giannakakis, K.
    Karasavvidis, V.
    Touriki, A. V.
    Argyropoulou, E.
    Valavani, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2109 - 2109
  • [36] Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
    Khalfallah, Mohamed
    Maria, Dina A.
    Allaithy, Amany
    GLOBAL HEART, 2022, 17 (01)
  • [37] Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial
    Amit, Guy
    Cafri, Carlos
    Yaroslavtsev, Sergei
    Fuchs, Shmuel
    Paltiel, Ora
    Abu-Ful, Akram
    Weinstein, Jean M.
    Wolak, Arik
    Ilia, Reuben
    Zahger, Doran
    AMERICAN HEART JOURNAL, 2006, 152 (05) : 887.e9 - 887.e14
  • [38] The impact of lesion complexity on no-reflow phenomenon and predictors of reversibility in patients treated with primary percutaneous intervention
    Durmaz, Eser
    Karadag, Bilgehan
    Ikitimur, Baris
    Atici, Adem
    Koca, Damla
    Mutlu, Deniz
    Soysal, Ali Ugur
    Raimoglu, Utku
    Ozmen, Emre
    Ohtaroglu Tokdil, Kardelen
    Incesu, Gunduz
    Ongen, Zeki
    CORONARY ARTERY DISEASE, 2020, 31 (08) : 678 - 686
  • [39] Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease
    Nagai, Toshiyuki
    Hirano, Takuro
    Tsunoda, Mayumi
    Hosaka, Haruhiko
    Kishino, Yoshikazu
    Katayama, Takaharu
    Matsumura, Keisuke
    Miyagawa, Takashi
    Kohsaka, Shun
    Anzai, Toshihisa
    Fukuda, Keiichi
    Suzuki, Masahiro
    HEART AND VESSELS, 2013, 28 (05) : 559 - 565
  • [40] Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
    Qi, Qi
    Niu, Jinghui
    Chen, Tao
    Yin, Hongshan
    Wang, Tao
    Jiang, Zhian
    MEDICAL SCIENCE MONITOR, 2018, 24 : 2767 - 2776